Objective Pharmacogenomics seeks to improve prescribing by reducing drug inefficacy/toxicity. However, views of patients during pharmacogenomic-guided care are largely unknown. We sought to understand the attitudes and perceptions of patients in an institutional implementation project and hypothesized that views would differ on the basis of experience with pharmacogenomic-guided care.
Introduction
Pharmacogenomics studies the genetic variability governing an individual's drug response, with the aim of improving prescribing by reducing drug inefficacy and toxicity. Despite this promise, its adoption has been encumbered by hurdles pertaining to process, providers, and patients [1] [2] [3] . Various solutions have been devised for the former two, including the creation of Clinical Pharmacogenetics Implementation Consortium guidelines to facilitate the use of pharmacogenomic information (process) [4, 5] , development of clinical decision supports to guide decision-making (process and providers) [6] , and providing pharmacogenomic education to healthcare professionals (providers) [7, 8] .
The role of patients as key stakeholders in the successful implementation of pharmacogenomics has received less practical attention during initial implementation efforts [9] [10] [11] [12] [13] [14] . Previous studies among patients and healthy volunteers reported a general receptiveness for pharmacogenomics to predict adverse effects and guide drug selection and dosing [9, 11] . One study solicited perceptions of patients who had undergone thiopurine methyltransferase genotyping before being prescribed azathioprine [15] , but the patients rarely recalled the test being performed. The views of patients who experienced broad, pre-emptive pharmacogenomic testing are largely unknown.
We sought to explore the attitudes and perceptions of pharmacogenomics among genotyped patients actively participating in an institutional pharmacogenomic implementation project compared with that of a control Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.pharmacogeneticsandgenomics.com).
group receiving traditional care. We hypothesized that patients' views of pharmacogenomics would differ significantly on the basis of whether they had experienced pharmacogenomic-guided care. We also aimed to illuminate important themes identified by patients that will be critical to the successful future expansion of pharmacogenomic adoption during clinical care.
Participants and methods

Participants
Study participants were recruited from an existing institutional pharmacogenomic implementation study called the 1200 Patients Project (clinicaltrials.gov #NCT0128 0825) [16, 17] . This project provided pre-emptive pharmacogenomic testing for up to 1200 patients receiving care from primary care and subspecialty physicians in an outpatient setting to assess the utility of pharmacogenomic results. Full operational details of the study have been previously published elsewhere [16, 17] . Briefly, participants in the genotype arm receive a short explanation of pharmacogenomics during study enrollment. A one-time blood sample is obtained for genotyping across a comprehensive panel of variants selected on the basis of their published evidence as impacting drug response or toxicity. Patients' pharmacogenomic results are then delivered to their enrolling study provider(s) by a secure, electronic medical record-embedded decision-support tool called the Genomic Prescribing System. This system indicates actionable pharmacogenomic information on the patient's current medications (and, on-demand, about any medications that the physician is considering prescribing) as traffic light signals (green, yellow, red, or dose calculator). Each signal is also accompanied by a concise but detailed pharmacogenomic information summary, with link-outs to support the primary literature. All providers in the study have the autonomy to decide whether to discuss with patients if the pharmacogenomic results are relevant and whether to act upon them. Adult patients were eligible if they were taking at least one regularly used prescription medication, but not more than six at the time of enrollment. Patients were initially enrolled into the genotyping cohort (pharmacogenomic group); enrollment into the non-genotyped cohort (traditional care group) began~1.5 years later, after which both groups concurrently enrolled up to 3600 (1200 genotyped/2400 nongenotyped) patients. Both cohorts received standard medical care by the same study providers.
Participants were contacted by phone for potential participation in the focus groups. We prespecified a sample size of 10-12 participants per group in accordance with published guidelines in the literature that recommend an ideal size of 4-12 participants per group [18, 19] . Purposeful sampling of both cohorts (with continual assessment of the demographics of confirmed participants to guide subsequent phone call invitations) was utilized to ensure a demographic composition within each focus group that was representative of the demographics of the larger overall 1200 Patients Project [16, 20, 21] . A recruitment transcript was used to explain the purpose of the focus group -to gather patient opinions on medication use, genetic testing, and their relationship with their physician and pharmacist. Potential participants were informed that they would be given a $50 gift card and complementary parking as an incentive for participation. A confirmation letter with the focus group details was mailed to individuals who agreed to participate. The overall 1200 Patients Project and this substudy were approved by the University of Chicago Institutional Review Board.
Study design and data collection
Both groups convened separately for 120-min sessions in July 2015. At the start of each session, participants were asked to complete a short demographic questionnaire. Each session was led by three facilitators (R.P.M., Y.M.L, and P.H.O) using a semistructured interview guide consisting of pretested questions (Supplementary methods, Supplemental digital content 1, http://links.lww.com/FPC/ B190) to facilitate the discussion. The interviews explored five domains: (i) participants' experiences with medications and side effects, (ii) understanding of pharmacogenomics, (iii) impact of pharmacogenomics on their relationship with physicians and pharmacists, (iv) responses to three pharmacogenomic case vignettes, and (v) responses to two publicly available pharmacogenomic education tools: https://medicine.uiowa.edu/humangenetics/humangenetics/ sites/medicine.uiowa.edu.humangenetics/files/wysiwyg_ uploads/CYP2C19.pdf and https://www.stjude.org/con tent/dam/en_US/shared/www/patient-support/do-youknows/pharmaco-slco1b1.pdf. Each focus group was audio-recorded with full participant knowledge and written transcripts were created with patient identifiers (e.g. names) redacted.
Data analysis
Thematic analysis of the anonymized transcripts was carried out using a combined deductive and inductive process [22] . This approach allowed for organizing a priori codes on the basis of research questions and developing de novo codes on the basis of emergent themes. A conceptual framework using themes derived from the previous literature on patients' knowledge and attitudes toward pharmacogenomics was used for the deductive portion. ATLAS.ti 7.5.10 (ATLAS.ti; GmbH, Berlin, Germany) was used to facilitate coding. Two investigators (R.P.M and Y.M.L) first reviewed a portion of the transcripts independently to develop the coding scheme, followed by a comparative analysis until thematic saturation was achieved. The agreed-upon coding framework was then applied to all transcripts with a comparison performed to establish inter-rater reliability (satisfactory κ score ≥ 0.75). The primary outcome was to identify themes and subthemes, and representative quotations for each.
Results
Patient demographics
We contacted 136 participants by phone: 53 did not answer, 51 refused or were unable to participate, and 32 agreed to participate. The most commonly cited reasons for declining participation were lack of interest, schedule conflict, and no means of transportation to get to the session. Ten participants who agreed by phone did not come to the focus group sessions (six in the pharmacogenomic group and four in the traditional care group), leaving nine and 13 participants in the pharmacogenomic and traditional care groups, respectively. The purposeful sampling method proved successful as the demographic characteristics of both groups were similar (Table 1) and were essentially identical to the overall larger institutional 1200 Patients Project population [21] : 50% were men, 55% were White, and the average age was 59.5 years. Notably, 64% of participants self-reported a history of medication-related side effects. Only three (33%) pharmacogenomic group participants recalled receiving a pharmacogenomic-determined prescription, whereas no traditional care participants reported that pharmacogenomics was used to choose their medications. The number of study provider encounters since the time of enrollment was similar between the pharmacogenomic (4.3 3.8) and the traditional care (3.9 2.0) groups (P = 0.70).
Eight major themes emerged from the two focus groups (Table 2) : participants' concerns when starting a new medication; factors influencing drug response; knowledge of genetics and pharmacogenomics; reasons to undertake a pharmacogenomic test; concerns about consenting to a pharmacogenomic test; concerns about privacy and personal pharmacogenomic information; relationship with healthcare professionals; and skepticism toward the medical field in general. The context from which these themes emerged is illustrated by a word cloud generated from the full reviewed transcripts (Fig. S1 , Supplemental digital content 2, http://links.lww. com/FPC/B191).
Participants' views on pharmacogenomics, testing, and related interests and concerns Each emergent major theme is discussed in detail below.
Concerns when starting a new medication
Participants in both groups wanted to know the potential side effects associated with any new medication prescribed. In addition, the pharmacogenomic group wanted to know whether the new medication was necessary and effective, what other therapeutic options were available, and the insurance coverage of the new medication. The traditional care group was more concerned about longterm effects of the medication, interactions with other medications, and whether there was sufficient research carried out with the new medication.
Factors influencing drug response
Both groups stated that an individual's activity level would influence his/her drug response, but only pharmacogenomic participants listed genetics and medication adherence as additional factors that could influence drug response.
Knowledge of genetics and pharmacogenomics
Before explaining pharmacogenomics, participants were asked to discuss how genetics influenced an individual's drug response. Both groups showed an understanding of genetics by relating it to traits inherited and traced through family history. The pharmacogenomic group had strong additional pharmacogenomics understanding, with one participant asking how pharmacogenomics informed a physician that one drug was better than another, stating: 'So what in my blood tells him that this drug is better than that drug?'. In contrast, the traditional care group universally confused pharmacogenomics with diseaserisk testing, with participants unable to provide a working definition of pharmacogenomics. Several traditional care participants remained confused about disease risk even after hearing (from the study investigators) a definition of pharmacogenomics and its potential applications. Reasons to undertake a pharmacogenomic test
The majority of participants in both groups expressed a strong general interest in the concept of pharmacogenomic testing. The most popular reason cited among the pharmacogenomic group was to inform physicians' decision-making as evidenced in the following comment: 'It would give us more information…and better inform as to what medication to prescribe'. The second most common reason was altruisticthe pharmacogenomic participants expressed a common desire (by their being tested themselves) to potentially help others find a more effective drug (i.e. more knowledge would be gained of how medications work in general if more patients underwent pharmacogenomic testing).
In contrast, the traditional care group was more narrowly supportive of pharmacogenomic testing to inform their physicians' decision-making and avoid medicationrelated side effects. One traditional care participant stated: 'I want to know if you could skip the side effects', and this was universally agreed within the group.
Concerns about consenting to a pharmacogenomic test
Both groups wanted to understand their underlying condition that prompted the pharmacogenomic test and subsequent prescribing of the pharmacogenomic drug. Participants were also concerned about whether pharmacogenomics would affect their insurance coverage and employment.
Unique concerns of the pharmacogenomic group included questions on the accuracy of the test, as exemplified by the following comment: 'How accurate is this genetic testing related to medications? Is there enough track record? Is it on target?'. The pharmacogenomic group was also concerned about treatment options available on the basis of their results as well as the differences between treatment options. There was also the question of ancillary information discovered, as highlighted in the following comment: 'There must be other information attached to whatever they found that made me genetically different from other people'. In contrast, traditional care participants asked about issues such as the cost of the test and why the test was not performed routinely: 'Shouldn't it be automatic when you go to the doctor, they try and do everything possible for a person?'.
Concerns about privacy and personal pharmacogenomic information
Several concerns were raised about pharmacogenomic testing, with participants in both groups sharply divided over the issue of privacy. The majority of both groups agreed that genetic information was sensitive and should be stored securely, but participants in both groups diverged in their views over who could access their pharmacogenomic results. Some participants felt that any physician should have access as long as it was relevant to their practice as exemplified in the following comment: 'The privacy part shouldn't matter. Both groups indicated that the nature of their relationship with the treating physician would influence their decision to undertake pharmacogenomic testing as shown in the following comment: '…if that had been my primary physician to suggest that…I would have said, 'Well okay, let's think about that. Let's talk some more'. But as far as me being in the emergency care, doctors I'm not familiar with…I know they got a protocol and Hippocratic Oath they must take…but, I'm not good with that in that situation'. Notably, the pharmacogenomic group expressed a high regard for physicians who adopted pharmacogenomics as a sign of staying at the forefront of medicine. One pharmacogenomic participant narrated his positive experience of receiving a pharmacogenomicdetermined prescription, stating: 'My physician tell me based on my pharmaco-blood test…I needed my blood pressure medication changed…I was assured that this was a good idea to participate…I think it's a real positive thing'.
When participants were asked what would impact their trust in their physicians, both groups listed various characteristics, namely, physicians' personalized knowledge of the participant, knowledge of the medical field, and willingness to refer participants to other providers for problems beyond their expertise. In addition, both groups desired physicians to show personal attention by taking time to listen and discuss issues with them: 'It does make a difference when your doctor takes time out with you to sit down and discuss everything, just don't be in a hurry'.
In terms of the relationship with their pharmacist, both groups agreed that pharmacogenomics could help pharmacists identify problem prescriptions: 'It would make the pharmacist more informed and again another double, triple check before they're handing me the medications'. However, one traditional care participant argued that it was redundant to share their pharmacogenomic information as physicians could check them when they prescribe. Another pharmacogenomic participant relied on his physician as his source of drug information, stating: '…my pharmacist is the mailman…my pharmacist doesn't exist', in reference to him obtaining his medicines by mail order.
Skepticism toward the medical field in general
The theme of skepticism uniquely emerged strongly in the traditional care group during the discussion on participants' concerns with starting new medications and consenting to a pharmacogenomic test. Some participants expressed deep mistrust in pharmaceutical companies for de-emphasizing the serious side effects of their advertised medicines as conveyed in the following comment: '…the television, if you see a certain medication, that you're taking, or you've been prescribed to take, and they'll say, real fast: 'Side effects of such and such…' Wait a minute, hold on, I'm gonna be dead by taking this stuff…or I'm gonna be crippled or something if I take this medication'. Another representative quotation from a traditional care participant was as follows: '…if I was gonna do this genetic testing it would have to be over more grave circumstances…if I don't do it, I'm gonna die'. One traditional care participant was skeptical of physicians' knowledge of medicines as he felt like a 'guinea-pig' being tested with new medicines, whereas other participants felt overmedicated by physicians who kept adding new medications.
Participants' responses to clinical prescribing vignettes involving warfarin, simvastatin, and clopidogrel
Participants' responses were elicited to three clinical vignettes that showed the different implications of using pharmacogenomic information. The first vignette showed how pharmacogenomic information predicted a lower warfarin dose because of CYP2C9 and VKORC1 gene polymorphisms. The second vignette involved a SLCO1B1 transporter variation that increased participants' risk for statin-induced myopathy, leading to a discussion (within the vignette) about sacrificing potential efficacy to avoid side effects by prescribing a potentially less effective cholesterol-lowering drug. The third vignette examined drug efficacy versus the cost of therapy where the participant had a CYP2C19 poor metabolizer genotype that precluded the use of clopidogrel in preference for a more expensive alternative antiplatelet agent.
In all three vignettes, common themes emerged from both groups as highlighted in Interestingly, participants expressed high expectations of drug efficacy with a pharmacogenomic-determined medication with the preparedness to tolerate side effects, as exemplified by the following comment: '…if I know it could be really effective…even if there might be some side effects then I might be more willing to push through, knowing the benefits'. There were also heightened worries about side effects, as in the following example: '…if you went into this with more information that you may be more predetermined to have these sideeffects. I think it would be even stronger notion that like if I throw up tomorrow that's probably the medicine, whether it was or not'.
Distinctive themes emerged from the different vignettes.
With the warfarin vignette, participants wanted to understand their underlying condition that prompted the pharmacogenomic-guided prescribing of warfarin. With the simvastatin vignette, participants were concerned as to how physicians would manage when the less effective cholesterol-lowering drug failed, but were simultaneously keen on dealing with side effects of the alternative treatment options. With the clopidogrel vignette, participants were concerned with insurance coverage of the expensive alternative and wanted to understand whether the therapeutic benefit justified the higher cost incurred: 'Is that the only reason that drug X was the preferred drug in the first place?…if there were other reasons I'd want to know what I was giving up, other than the cost. And then I'd be interested in who covers the cost'.
Participant perspectives on pharmacogenomic education materials
Participants were asked to critically evaluate two publicly available pharmacogenomic education handouts with the aim of understanding how pharmacogenomic information could best be presented (Table 4) .
Participants favored a bullet point layout with both handouts as it made the information easier to read and understand. With the simvastatin handout, one participant found the explanation of the physiology behind pharmacogenomics helpful, as exemplified by the following comment: 'This is the kind of thing they're talking about, this is how it works, this is interesting'. However, the technical language and heavy use of acronyms caused some confusion among some participants, with one participant stating that the simvastatin handout was 'pretty technical for a layperson to understand'. The clopidogrel handout also elicited conflicting views, with one participant stating that it was '[more] complicated' and the pictures were 'very uninformative', whereas other participants found the handout 'pretty straightforward'. Participants questioned the completeness of the clopidogrel pharmacogenomic test as prompted by the handout's information that the test only interrogated the common variants associated with clopidogrel, leaving concerns as to whether there were 'important things…not captured?' as one participant asked.
With respect to the type of pharmacogenomic information provided, one participant preferred the content to be patient specific than general as shown in the following comment: 'I don't care about the statistics of other people because I'm hoping I'm the exception; so you address me personally…I want it to be me…All about me'. In contrast, another participant was comfortable with having general information to convey the risk versus benefit ratio as in the following comment: 'I think numbers can be important, and I think we all can be the exception to anything, but if the doctor tells me I've got an 80 percent higher risk, if I don't take this, and the side-effects aren't that bad, and even if they are…does it outweigh me dying?'. Both groups favored having handouts (compared with not), but did not want handouts to replace opportunities to discuss pharmacogenomic information with their physicians in person. In contrast, we elicited a strong desire on the part of patients for physicians to engage participants when considering pharmacogenomicbased prescribing and to utilize shared decision-making. Participants also requested access to alternative information sources such as internet websites and online videos.
Discussion
In this study, we explored the attitudes and perceptions of participants exposed to pharmacogenomic-guided care versus those receiving traditional care. Participants who had experienced pharmacogenomic-guided care showed a better understanding of pharmacogenomics and were more receptive toward the use of their pharmacogenomic information, whereas traditional care participants showed greater skepticism about how their genomic information might be used. Both groups held similar concerns in terms of insurance coverage and employment discrimination and had widely ranging views about who should access pharmacogenomic results. These themes identify key topics to be addressed during the implementation of pharmacogenomic testing.
Our results point toward the need for physicians to engage participants during pharmacogenomic-guided prescribing. Participants nearly universally agreed that pharmacogenomics could potentially inform physicians' prescribing decisions to maximize drug efficacy and minimize side effects, as well as help pharmacists identify problem prescriptions. These results indicate that the general promise of precision medicine is both perceived and understood by most participants. To this point, traditional care participants even asked why pharmacogenomic testing was not performed routinely as part of standard care, echoing the sentiments of patients from other studies who showed a strong general receptiveness toward pharmacogenomics [11] .
However, the participants had some appropriate reservations about the implementation of pharmacogenomics. Skepticism about how pharmacogenomic information might be used, especially among the study participants who had not been genotyped before, was a common theme. The question of who should be granted access to genomic results was the most hotly debated topic of both focus groups, with most participants having strong, vocal opinions, distributed across the spectrum on the subject of genomic test privacy. It was interesting to note that although both groups agreed that pharmacogenomic results should be securely stored, they diverged over who should access results, ranging from strict views that only a personal, longstanding treating physician should have access, to others arguing for complete, world-wide open access among healthcare professionals. The former view contrasted that of another study, where 90% of respondents were extremely or somewhat comfortable sharing their pharmacogenomic results with other physicians involved in their care [10] . Our study also found mixed views among participants about sharing their pharmacogenomic information with pharmacists, in contrast with other studies where at least 70% of individuals would share their results with their pharmacists [10, 13] . In addition, we found that both genotyped and nongenotyped participants had concerns over insurance coverage, employment discrimination, and cost implications of pharmacogenomic-guided care, all of which have similarly been reported in previous studies [9,11-13,23 -25] . As cost/reimbursement considerations remain one of the greatest barriers to more universal adoption of pharmacogenomics, these considerations will need to be addressed by practice-based or institutional standards during early phases of implementation.
The use of pharmacogenomic patient education materials could facilitate discussions around these important themes. Indeed, we plan to use the findings of this study to help create pharmacogenomic education materials that can be utilized to introduce the idea of pharmacogenomic testing to future patients and as resources for patients already receiving pharmacogenomic-guided care. One hope is that such materials would augment the overall educational process that providers must engage in and simultaneously assuage potential participants' common concerns. Importantly, these materials should be used as vehicles to facilitate in-person discussions around these topics rather than as replacements for such discussions. Participants also wanted to understand the different treatment options available, the rationale behind a pharmacogenomic-guided selection, and side-effect/efficacy tradeoffs. We even elicited the idea that patients might be more willing to tolerate a drug with some degree of side effects if they knew (on the basis of their pharmacogenomic information) that a drug was more likely to be effective. This potential for pharmacogenomics to impact participants' medication adherence is in agreement with the findings of another study where higher statin therapy adherence was reported among patients who were informed of their pharmacogenomic results than controls who were not [26] . To the contrary, participants wondered about their preconceived heightened sensitivity toward side effects on the basis of their pharmacogenomic results. Thus, although it is important to promote participants' comprehension of their pharmacogenomic results, this must be balanced with avoiding unnecessary adverse or inappropriate psychological or behavioral patient responses [27] . The educational content should also address the important difference between pharmacogenomic and disease-risk testing as has been suggested previously in other studies [24] .
This study had several limitations. First, participants were recruited from an existing institutional pharmacogenomic implementation study where the participants' relationships with their physician could have influenced their decision to enroll, hence potentially introducing bias with the self-selection of a highly interested group. The larger study (The 1200 Patients Project) was also nonrandomized. Second, although our study did not ascertain whether some patients were simply more informed about pharmacogenomics a priori versus whether the experience of participating in this study constituted an important primary education, it is nonetheless possible that the pharmacogenomic group participants may have been more receptive to pharmacogenomicguided care simply because they received additional education and exposure to the subject during enrollment and participation. If this is true, it would suggest that general public acceptance of genomic-guided care will only increase as the practice becomes more mainstream and as immersive education occurs. Third, the focus groups were held during the daytime of a work week; thus, they were a convenience sample of participants who were available to attend the sessions. Nevertheless, the demographic characteristics of the participants matched those of the larger study (which has now enrolled > 1400 patients) and the emergent themes from the focus groups dovetail with those that have emerged from other studies in this arena. The major advantage of our work compared with all other previous studies is that we examined both patients who had never been genotyped alongside patients who had been pharmacogenomically tested and were actively being treated within physician practices where pharmacogenomic information was routinely being utilized.
Conclusion
We found that participants who experienced pharmacogenomic-guided care had a better understanding of pharmacogenomics and were more receptive toward the use of their information compared with traditional care participants who were generally more skeptical. Physicians need to actively engage participants during the testing and prescribing processes as participants' perceptions of pharmacogenomics and genomicdetermined prescribing may influence their perceptions of anticipated medication efficacy and side effects. As adoption of pharmacogenomic testing becomes more widespread, understanding patients' attitudes and perceptions of pharmacogenomics and addressing concerns will become increasingly important in the design of pharmacogenomic implementation models.
